Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Intravacc B.V.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ITV2002 | P1 |
Completed |
COVID-19 |
2023-08-09 |
23% |
2024-03-23 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/26/2024 |
News Article |
Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2 |
|
11/30/2022 |
News Article |
Intravacc launches phase I clinical trial of Avacc 10®, an intranasal subunit booster vaccine for SARS-CoV-2 |
|
10/31/2022 |
News Article |
EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine |
|
10/06/2022 |
News Article |
CEPI partners with Intravacc to develop an intranasal, broadly protective Betacoronavirus vaccine |